NEWS

Oneness Biotech has licensed out OB318, a novel drug candidate for hepatocellular carcinoma to Microbio Shanghai for co-development and commercialization in mainland China, Hong Kong and Macao.

2017-11-10

Oneness Biotech has signed an exclusive licensing agreement with Microbio Shanghai for the development of OB318. Under the agreement, Microbio Shanghai will cover the development and commercialization of OB318 in mainland China, Hong Kong and Macao. The license payment will be converted into investment in company shares of MicroBio Shanghai.

關閉

建議您使用以下瀏覽器觀看合一網站,
以獲得最佳瀏覽效果。

要下載瀏覽器,請直接點擊以下: IE瀏覽器現已不支援大多數網站,並將於2022年6月終止服務

如何使用IE找到Microsoft Edge?

  1. 開啟新分頁(紅色框)
    開啟新分頁
  2. 於搜尋框中打入Edge(紅色框),並按搜尋(藍色框)
    於搜尋框中打入Edge,並按搜尋
  3. 點擊【立即啟動】(藍框處)打開 Microsoft Edge
    啟動Microsoft Edge